Cargando…
Prevention of metastasis from mouse mammary carcinomas with liposomes carrying doxorubicin.
Weekly treatments with doxorubicin encapsulated in long circulating, sterically stabilised liposomes (DOX-SL) reduced the incidence of metastases from primary mammary carcinoma from 24 of 47 untreated mice to 3 of 23 treated mice. Toxic side-effects were limited to minor, transient weight losses.
Autores principales: | Vaage, J., Donovan, D., Loftus, T., Working, P. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1995
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033931/ https://www.ncbi.nlm.nih.gov/pubmed/7577449 |
Ejemplares similares
-
Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma.
por: Vaage, J., et al.
Publicado: (1997) -
Lipodox® (generic doxorubicin hydrochloride liposome injection): in vivo efficacy and bioequivalence versus Caelyx® (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mouse models
por: Burade, Vinod, et al.
Publicado: (2017) -
Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma
por: Nik, Maryam Ebrahimi, et al.
Publicado: (2019) -
Author Correction: Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma
por: Nik, Maryam Ebrahimi, et al.
Publicado: (2020) -
Comparative effects of free doxorubicin, liposome encapsulated doxorubicin and liposome co-encapsulated alendronate and doxorubicin (PLAD) on the tumor immunologic milieu in a mouse fibrosarcoma model
por: Islam, Md. Rakibul, et al.
Publicado: (2022)